(Q35602676)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662002%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

review article

1 reference

title

Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662002%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662002%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Michele Orditura

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662002%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Giampaolo Tortora

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662002%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

author name string

Ferdinando De Vita

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662002%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Sabino De Placido

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662002%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

language of work or name

English

0 references

publication date

1 November 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662002%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Emerging Drugs

21 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662002%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662002%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662002%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

page(s)

501-514

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662002%20AND%20SRC:MED&resulttype=core&format=json

Epidermal growth factor-related peptides and their receptors in human malignancies

21 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.2.501

The epidermal growth factor receptor as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.2.501

Autocrine secretion and malignant transformation of cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.2.501

The EGF receptor family as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.2.501

Antitumor Activity of Combined Blockade of Epidermal Growth Factor Receptor and Protein Kinase A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.2.501

Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.2.501

Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.2.501

ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.2.501

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.2.501

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.2.501

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.2.501

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.2.501

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.2.501

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.2.501

ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.2.501

A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.2.501

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.2.501

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.2.501

Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.2.501

Targeting epidermal growth factor receptor--are we missing the mark?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.2.501

Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.2.501

Developing inhibitors of the epidermal growth factor receptor for cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.2.501

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.2.501

Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.2.501

21 January 2018

Identifiers

DOI

10.1517/14728214.8.2.501

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662002%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference